MX2019010679A - Usl-311 para uso en el tratamiento de cancer. - Google Patents

Usl-311 para uso en el tratamiento de cancer.

Info

Publication number
MX2019010679A
MX2019010679A MX2019010679A MX2019010679A MX2019010679A MX 2019010679 A MX2019010679 A MX 2019010679A MX 2019010679 A MX2019010679 A MX 2019010679A MX 2019010679 A MX2019010679 A MX 2019010679A MX 2019010679 A MX2019010679 A MX 2019010679A
Authority
MX
Mexico
Prior art keywords
treatment
usl
cancer
diazepan
propan
Prior art date
Application number
MX2019010679A
Other languages
English (en)
Inventor
Richardson Peter
Original Assignee
Proximagen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Llc filed Critical Proximagen Llc
Publication of MX2019010679A publication Critical patent/MX2019010679A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona al uso del antagonista CXCR4 6-{4-[1-(Propan-2- il) piperidin-4-il]-1,4-diazepan-1-il} N(piridin-4-il)piridin-2-carboxamida o una sal farmacéuticamente aceptable de la misma en el tratamiento de cánceres del seno, vejiga, colon, recto e hígado.
MX2019010679A 2017-03-10 2018-03-09 Usl-311 para uso en el tratamiento de cancer. MX2019010679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703907.4A GB201703907D0 (en) 2017-03-10 2017-03-10 Novel therapies for cancer
PCT/GB2018/050608 WO2018162924A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019010679A true MX2019010679A (es) 2020-02-05

Family

ID=58605592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010679A MX2019010679A (es) 2017-03-10 2018-03-09 Usl-311 para uso en el tratamiento de cancer.

Country Status (14)

Country Link
US (1) US20200281937A1 (es)
EP (1) EP3592356A1 (es)
JP (1) JP2020514345A (es)
KR (1) KR20190128660A (es)
CN (1) CN110520130A (es)
AU (1) AU2018231664A1 (es)
BR (1) BR112019018482A2 (es)
CA (1) CA3055470A1 (es)
EA (1) EA201992130A1 (es)
GB (1) GB201703907D0 (es)
IL (1) IL269121A (es)
MX (1) MX2019010679A (es)
SG (1) SG11201908166UA (es)
WO (1) WO2018162924A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
BR112017019437A2 (pt) 2015-04-02 2018-05-02 Proximagen Ltd terapias para câncer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
BR112017019437A2 (pt) * 2015-04-02 2018-05-02 Proximagen Ltd terapias para câncer
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy

Also Published As

Publication number Publication date
US20200281937A1 (en) 2020-09-10
WO2018162924A1 (en) 2018-09-13
EP3592356A1 (en) 2020-01-15
IL269121A (en) 2019-11-28
CN110520130A (zh) 2019-11-29
GB201703907D0 (en) 2017-04-26
AU2018231664A1 (en) 2019-09-26
CA3055470A1 (en) 2018-09-13
BR112019018482A2 (pt) 2020-04-14
JP2020514345A (ja) 2020-05-21
SG11201908166UA (en) 2019-10-30
EA201992130A1 (ru) 2020-02-04
KR20190128660A (ko) 2019-11-18

Similar Documents

Publication Publication Date Title
MX2017011981A (es) Terapias novedosas para cancer.
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2020000690A (es) Compuestos heterociclicos como antagonistas de adenosina.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
UA118113C2 (uk) Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
SG10201902664RA (en) Combination therapy for treating cancer
PH12015502159A1 (en) Chemical entities
PH12017500163A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX2016016490A (es) Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos.
BR112018067938A2 (pt) combinação de um antagonista de cxcr4 e inibidor de ponto de verificação imunológica
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MX2020000693A (es) Compuestos de 1,8-naftiridinona, y usos de los mismos.
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
PH12018502360A1 (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2019010679A (es) Usl-311 para uso en el tratamiento de cancer.
MX2015012386A (es) Inhibidores de la cinasa cdk9.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase